A proof of concept clinical study of tafasitamab with lenalidomide and plamotamab in r/r B-cell malignancies
Latest Information Update: 01 Mar 2022
At a glance
- Drugs Lenalidomide (Primary) ; Plamotamab (Primary) ; Tafasitamab (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Proof of concept; Registrational; Therapeutic Use
- 23 Feb 2022 According to a Xenor media release, the company is currently opening clinical sites for the potentially registration-enabling Phase 2 study, evaluating plamotamab in combination with tafasitamab and lenalidomide, in patients with relapsed or refractory DLBCL.
- 04 May 2021 According to an Incyte media release, the company plans to initiate this study later this year or early next year.
- 15 Feb 2021 New trial record